New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population.
about
Assessing compliance of cardiologists with the national cholesterol education program (NCEP) III guidelines in an ambulatory care settingBeyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)National trends in statin use by coronary heart disease risk categoryCoronary risk assessment by point-based vs. equation-based Framingham models: significant implications for clinical care.Statins: balancing benefits, efficacy and safety.Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys.Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemiaRenin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management.Impaired aortic distensibility measured by computed tomography is associated with the severity of coronary artery diseaseCD31+ T cells, endothelial function and cardiovascular riskEnhanced endothelin-1 system activity with overweight and obesityUpdate on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal.Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.Statins: can the new generation make an impression?Effects of Adherence to Statin Therapy on Health Care Outcomes and Utilizations in Taiwan: A Population-Based Study.Cost-utility analysis of a national project to reduce hypertension in IsraelOverprescribing of lipid lowering agents.Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adultsImpaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonistsRandomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipidsAssessment of global coronary heart disease risk in overweight and obese African-American women.Application of national screening criteria for blood pressure and cholesterol to perimenopausal women: prevalence of hypertension and hypercholesterolemia in the Study of Women's Health Across the Nation.Costs of dyslipidemia.Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.Identification of gene-selective modulators of the bile acid receptor FXR.Ezetimibe: a novel option for lowering cholesterol.Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise.Acute and chronic effects of vitamin C on endothelial fibrinolytic function in overweight and obese adult humans.Blood Pressure Regulation: Reviewing Evidence for Interplay Between Common Dietary Sugars and Table Salt.The clinical and nonclinical values of nonexercise estimation of cardiovascular endurance in young asymptomatic individuals.
P2860
Q24794337-FD5DC875-9845-4EC0-848B-35C129EF6B40Q24795084-0CB30F79-43FD-4821-8B7A-D3F2D0409961Q24810059-B694C734-D32B-419B-901B-369F2D11BD1FQ34164321-898FFA4B-1ACB-48DB-B625-6E31F6BD58D8Q34628565-A20D74A7-4DDF-4FA6-AE7B-2117D573DC92Q34657896-0AD84F6A-AD23-4E69-95D1-0E122E7C9AEDQ34704310-287A876B-3EE5-4C72-8ABE-9C68BE963073Q34849588-D2FCEA2C-077E-43FC-93AB-72A8C424CDE8Q34971125-A2D0D6F8-1C4C-4623-A401-184C827572A3Q35223745-3D72FE7C-89A0-42FC-9F52-0A3F69EA9D93Q35314860-5B83FD4D-D6AF-4878-A526-C4437FF97DDDQ35549732-EA17C34E-167D-4125-9941-0140E99FD423Q35696163-32BB6530-47BC-48B0-974C-23F789CD065CQ35967383-51971557-948E-499A-955C-635F9B5764D6Q36203999-88DD480B-1CCF-4ABA-97B9-6AEB2C8619E4Q36412316-FE466504-735E-4197-8B90-DDE75CFDE0C9Q36555257-8E96C251-3EDF-4105-8E7E-A8504AB4A2FAQ36880464-11154FB0-B924-4B83-919E-CC21F33BAA0FQ36938950-CDA1B3F1-4DBC-45F2-84E1-7E1B36E650C7Q37085308-A1AAE6E2-0EC8-47F2-B249-C3EF6674990CQ39649055-159CFFC7-03BD-49CF-A5F0-56796E271DA4Q40306023-0A63EF49-72D3-438B-94A9-611CDE763045Q40585105-EB4AFEAA-3333-4D44-8377-00778F368649Q44171842-617E1B4E-19E0-4C08-B47A-915EC41E706CQ44259003-7D13B004-8BF1-48A3-BC31-1807410F85C3Q44804875-0C521A75-5395-4215-83C8-559197128CA5Q46572738-0EA62B72-B354-441C-992C-56C548A12177Q46578793-251F3B69-6AE4-4925-8FC6-8C39A62B74FDQ46619645-6131F561-D2E3-4A34-905F-7D81441736ACQ55359870-A174A7AB-478E-4D2B-A003-125D67FE2985
P2860
New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
New National Cholesterol Educa ...... treatment-eligible population.
@en
New National Cholesterol Educa ...... treatment-eligible population.
@nl
type
label
New National Cholesterol Educa ...... treatment-eligible population.
@en
New National Cholesterol Educa ...... treatment-eligible population.
@nl
prefLabel
New National Cholesterol Educa ...... treatment-eligible population.
@en
New National Cholesterol Educa ...... treatment-eligible population.
@nl
P2093
P356
P1433
P1476
New National Cholesterol Educa ...... treatment-eligible population.
@en
P2093
Carol E Koro
Donald O Fedder
Gilbert J L'Italien
P304
P356
10.1161/HC0202.101971
P407
P577
2002-01-01T00:00:00Z